Drug development blossoms for rare, fatal bone disease.


Journal

Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511

Informations de publication

Date de publication:
31 May 2024
Historique:
medline: 30 5 2024
pubmed: 30 5 2024
entrez: 30 5 2024
Statut: ppublish

Résumé

Five drugs are now approved or in trials for genetic condition that triggers misplaced bone growth.

Identifiants

pubmed: 38815021
doi: 10.1126/science.adq7356
doi:

Substances chimiques

odanacatib N673F6W2VH
romosozumab 3VHF2ZD92J
Antibodies, Monoclonal 0
Biphenyl Compounds 0

Types de publication

News

Langues

eng

Sous-ensembles de citation

IM

Pagination

943-944

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH